- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT05025072
A Bioequivalence Study to Compare the Pharmacokinetics of Two Formulations of Hydroxycarbamide in Healthy Volunteers
This study is a Phase I, open-label, single-centre, randomised, two-period, single-dose crossover study to compare and assess the bioequivalence, safety, tolerability and pharmacokinetics of hydroxycarbamide dispersible tablets (20 x 50 mg) (test IMP) and hydroxycarbamide film-coated tablet (1000 mg) (reference IMP) following single-dose administration. Thirty (30) healthy male and female participants, between 18 and 50 years of age are planned to participate in the study.
Study participants will be randomised to one of the 2 possible combination sequences. After each treatment administration, blood samples will be collected at specific time points to assess the Pharmacokinetics (PK) parameters.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 1
Contactos e Locais
Locais de estudo
-
-
-
Merthyr Tydfil, Reino Unido
- Simbec-Orion Clinical Pharmacology
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Healthy male and female participants, between 18 and 50 years of age, inclusive.
- Female participant of childbearing potential willing to use a highly effective method of contraception, if applicable from the first dose until 3 months after the last dose of IMP.
- Female participant of non-childbearing potential. For the purposes of this study, this is defined as the participant being amenorrhoeic for at least 12 consecutive months or at least 4 months post-surgical sterilisation.
- Female participant with a negative pregnancy test at Screening.
- Male participant (and partner of child bearing potential) willing to use a highly method of contraception, if applicable from first dose until 3 months after last dose of IMP.
- Participant with a BMI of 18-29.9 kg/m2.
- No clinically significant history of previous allergy / sensitivity to hydroxycarbamide or any of the excipients contained within the IMP(s).
- No clinically significant abnormal test results for serum biochemistry, haematology and/or urine analyses within 28 days before the first dose administration of the IMP.
- Participant with a negative urinary DOA screen (including alcohol) test results, determined within 28 days before the first dose administration of the IMP.
- Participant with negative human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) and hepatitis C virus antibody (HCV Ab) test results at Screening.
- No clinically significant abnormalities in 12-lead ECG determined within 28 days before the first dose of IMP.
- No clinically significant abnormalities in vital signs determined within 28 days before the first dose of IMP.
- Participant must be available to complete the study.
- Participant must satisfy an Investigator about his/her fitness to participate in the study.
- Participant must provide written informed consent to participate in the study.
Exclusion Criteria:
- A clinically significant history of gastrointestinal disorder likely to influence IMP absorption.
- Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements within 28 days or 5 half-lives prior to the first dose of IMP.
- Evidence of renal, hepatic, central nervous system, respiratory, cardiovascular, or metabolic dysfunction.
- A clinically significant history of drug or alcohol abuse within the past two years.
- Inability to communicate well with the Investigators.
- Participation in a New Chemical Entity clinical study within the previous 3 months or five half-lives whichever is the longest, or a marketed drug clinical study within the 30 days or five half-lives whichever is the longest, before the first dose of IMP.
- Donation of 450 mL or more blood within the 3 months before the first dose of IMP.
- Users of nicotine products i.e., current smokers or ex-smokers who have smoked within 6 months prior to Screening or users of cigarette replacements
- Female participants who are pregnant, breastfeeding or lactating.
- Participants who have received any live or attenuated vaccine within 28 days of the first dose of IMP, or who are planning to receive a vaccine up to 28 days after receiving the last dose of IMP in Treatment Period 2.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Outro
- Alocação: Randomizado
- Modelo Intervencional: Atribuição cruzada
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Sequence A
Hydroxycarbamide dispersible tablets (20 x 50 mg) then Hydroxycarbamide film-coated tablet (1000 mg) |
Hydroxycarbamide dispersible tablets (20 x 50 mg) Hydroxycarbamide film-coated tablet (1000 mg) |
|
Experimental: Sequence B
Hydroxycarbamide film-coated tablet (1000 mg) then Hydroxycarbamide dispersible tablets (20 x 50 mg) |
Hydroxycarbamide dispersible tablets (20 x 50 mg) Hydroxycarbamide film-coated tablet (1000 mg) |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Cmax
Prazo: Day 1: prior to dose, 10 mins, 15 mins, 30 mins, 45 mins, 1 hr, 1 hr 30 mins, 2 hr, 4 hr, 6 hr, 8 hr, 12 hr, 18 hr post-Day 1 dose Day 2: 24 hr post-Day 1 dose
|
The observed maximum concentration (Cmax) in plasma |
Day 1: prior to dose, 10 mins, 15 mins, 30 mins, 45 mins, 1 hr, 1 hr 30 mins, 2 hr, 4 hr, 6 hr, 8 hr, 12 hr, 18 hr post-Day 1 dose Day 2: 24 hr post-Day 1 dose
|
|
AUC0-infinity
Prazo: Day 1: prior to dose, 10 mins, 15 mins, 30 mins, 45 mins, 1 hr, 1 hr 30 mins, 2 hr, 4 hr, 6 hr, 8 hr, 12 hr, 18 hr post-Day 1 dose Day 2: 24 hr post-Day 1 dose
|
The AUC from time 0 to infinity |
Day 1: prior to dose, 10 mins, 15 mins, 30 mins, 45 mins, 1 hr, 1 hr 30 mins, 2 hr, 4 hr, 6 hr, 8 hr, 12 hr, 18 hr post-Day 1 dose Day 2: 24 hr post-Day 1 dose
|
|
AUC0-t
Prazo: Day 1: prior to dose, 10 mins, 15 mins, 30 mins, 45 mins, 1 hr, 1 hr 30 mins, 2 hr, 4 hr, 6 hr, 8 hr, 12 hr, 18 hr post-Day 1 dose Day 2: 24 hr post-Day 1 dose
|
The area under the plasma concentration-time curve from time zero (pre-dose) to the time of last quantifiable concentration (t) |
Day 1: prior to dose, 10 mins, 15 mins, 30 mins, 45 mins, 1 hr, 1 hr 30 mins, 2 hr, 4 hr, 6 hr, 8 hr, 12 hr, 18 hr post-Day 1 dose Day 2: 24 hr post-Day 1 dose
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Tmax
Prazo: Day 1: prior to dose, 10 mins, 15 mins, 30 mins, 45 mins, 1 hr, 1 hr 30 mins, 2 hr, 4 hr, 6 hr, 8 hr, 12 hr, 18 hr post-Day 1 dose Day 2: 24 hr post-Day 1 dose
|
The time at which Cmax is apparent |
Day 1: prior to dose, 10 mins, 15 mins, 30 mins, 45 mins, 1 hr, 1 hr 30 mins, 2 hr, 4 hr, 6 hr, 8 hr, 12 hr, 18 hr post-Day 1 dose Day 2: 24 hr post-Day 1 dose
|
|
t1/2
Prazo: Day 1: prior to dose, 10 mins, 15 mins, 30 mins, 45 mins, 1 hr, 1 hr 30 mins, 2 hr, 4 hr, 6 hr, 8 hr, 12 hr, 18 hr post-Day 1 dose Day 2: 24 hr post-Day 1 dose
|
The terminal elimination half-life |
Day 1: prior to dose, 10 mins, 15 mins, 30 mins, 45 mins, 1 hr, 1 hr 30 mins, 2 hr, 4 hr, 6 hr, 8 hr, 12 hr, 18 hr post-Day 1 dose Day 2: 24 hr post-Day 1 dose
|
|
Adverse Events
Prazo: Day-1, Day1, Day2 of each treatement period, and up to the end of study visit which occured 1 to 3 days post last IMP administration for a maximum duration of approximately 7 weeks per participant.
|
Number of participants with Adverse Events |
Day-1, Day1, Day2 of each treatement period, and up to the end of study visit which occured 1 to 3 days post last IMP administration for a maximum duration of approximately 7 weeks per participant.
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Annelize Koch, MD, Simbec-Orion Group
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- SIK-FR-21-1
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .